Figure legends
Figure 1. Flow diagram depicting the study selection process.
Figure 2. MHD at three time points: baseline and after the administration of 3 and 6 doses of the correspondent treatment. Patients were clustered as follows: (A) CM treated with erenumab, (B) CM treated with galcanezumab, (C) EM treated with erenumab and (D) EM treated with galcanezumab. Dots/squares represent the means and vertical lines ± the standard error of the mean. * Represents values from treated groups that differ significantly from baseline status (RM One Way ANOVA, p < 0.05).
Figure 3. AMSMD at three time points: baseline and after the administration of 3 and 6 doses of the correspondent treatment. Patients were clustered as follows: (A) CM treated with erenumab, (B) CM treated with galcanezumab, (C) EM treated with erenumab and (D) EM treated with galcanezumab. Dots/squares represent the means and vertical lines ± the standard error of the mean. * Represents values from treated groups that differ significantly from baseline status (RM One Way ANOVA, p < 0.05).
Figure 4. HIT-6 scores at three time points: baseline and after the administration of 3 and 6 doses of the correspondent treatment. Patients were clustered as follows: (A) CM treated with erenumab, (B) CM treated with galcanezumab, (C) EM treated with erenumab and (d) EM treated with galcanezumab. Columns represent the means and vertical lines ± the standard error of the mean. * Represents values from treated groups that differ significantly from baseline status (RM One Way ANOVA, p < 0.05).
Figure 5. MIDAS scores at three time points: baseline and after the administration of 3 and 6 doses of the correspondent treatment. Patients were clustered as follows: (A) CM treated with erenumab, (B) CM treated with galcanezumab, (C) EM treated with erenumab and (D) EM treated with galcanezumab. Columns represent the means and vertical lines ± the standard error of the mean. * Represents values from treated groups that differ significantly from baseline status (RM One Way ANOVA, p < 0.05).
Figure 6. VAS scores at three time points: baseline and after the administration of 3 and 6 doses of the correspondent treatment. Patients were clustered as follows: (A) CM treated with erenumab, (B) CM treated with galcanezumab, (C) EM treated with erenumab and (D) EM treated with galcanezumab. Columns represent the means and vertical lines ± the standard error of the mean. * Represents values from treated groups that differ significantly from baseline status (RM One Way ANOVA, p < 0.05). # Represents values from treated groups that differ significantly from each other.